Dishevelled Segment Polarity Protein 1 (DVL1) Peptide
DVL1
适用: 人
宿主: 合成
BP, WB
-
- 抗原 See all DVL1 products
- DVL1 (Dishevelled Segment Polarity Protein 1 (DVL1))
- 宿主
- 人
-
资源
- 合成
- 应用范围
- Blocking Peptide (BP), Western Blotting (WB)
- 产品特性
- This is a synthetic peptide designed for use in combination with anti-DVL1 antibody (Catalog #: ARP32100_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- 纯化方法
- Purified
-
-
- 应用备注
- Each Investigator should determine their own optimal working dilution for specific applications.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- 浓度
- 1 mg/mL
- 缓冲液
- Final peptide concentration is 1 mg/mL in PBS.
- 注意事项
- Avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- 抗原
- DVL1 (Dishevelled Segment Polarity Protein 1 (DVL1))
- 背景
-
DVL1 is a cytoplasmic phosphoprotein that regulates cell proliferation, acting as a transducer molecule for developmental processes, including segmentation and neuroblast specification. DVL1 gene is a candidate for neuroblastomatous transformation. The Schwartz-Jampel syndrome and Charcot-Marie-Tooth disease type 2A have been mapped to the same region as DVL1 gene. The phenotypes of these diseases may be consistent with defects which might be expected from aberrant expression of a DVL gene during development.
Alias Symbols: DVL, MGC54245, DVL1L1
Protein Interaction Partner: ARRB1,AXIN1,BRD7,CCDC88C,CSNK1D,CSNK1E,CSNK2A1,CTNNB1,CXXC4,DAAM1,DVL1,DVL3,DYNLT1,EPS8,FRAT1,HDHD2,HECW1,PPM1A,RAC1,SMAD2,SMAD3,SMAD4,SMAD7,USP13,VANGL1,VANGL2,ARRB1,ATN1,AXIN1,Axin1,CSNK1D,CSNK1E,CSNK2A1,CTNNB1,DAB2,DVL1,DVL3,EPS8,FRAT1,HECW1,SMAD1,SMAD2,SMAD3,SMAD4,SMAD7,USP13
Protein Size: 353 - 分子量
- 38 kDa
- 基因ID
- 1855
- NCBI登录号
- NM_004421
- UniProt
- A6NKG8
-
You are here:
